[1] Retatrutide: What the Evidence Actually Shows Retatrutides pivotal obesity dataset is a Phase 2, double-blind, randomised, placebo-controlled trial in adults with obesity (or overweight plus a weight-related condition), testing once-weekly doses up to 12 mg over 48 weeks
This helps TSA agents quickly verify the medication
Participants with fetal alcohol syndrome, serious neurological disorders, metabolic, psychiatric, cardiovascular, or endocrine system disorders were also excluded
In humans, the clinical significance is unclear, but baseline and periodic calcitonin monitoring is recommended especially with prolonged use
Storage: Keep the medication refrigerated and shield it from light